Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13417736 | 0.89 | RIPK1 (0.38) | HTR2AHTR2CHTR2BHPGDRIPK1 | |
| SCHEMBL12366452 | 0.88 | RIPK1 (0.37) | HTR2AHTR2CHTR2BHPGDRIPK1 | |
| SCHEMBL2262979 | 0.88 | RIPK1 (0.37) | HTR2AHTR2CHTR2BHPGDRIPK1 | |
| SCHEMBL2262973 | 0.88 | RIPK1 (0.37) | HTR2AHTR2CHTR2BHPGDRIPK1 | |
| SCHEMBL2261794 | 0.86 | PDE4B (0.35) | HTR2AHTR2CHTR2BRIPK1 | |
| SCHEMBL12366348 | 0.86 | RIPK1 (0.36) | HTR2AHTR2CHTR2BHPGDRIPK1 | |
| SCHEMBL2261791 | 0.86 | PDE4B (0.35) | HTR2AHTR2CHTR2BRIPK1 | |
| SCHEMBL18509998 | 0.86 | SLC6A4 (0.39) | SLC6A4HTR6MCHR1PARP10HTR2A | |
| SCHEMBL13417733 | 0.85 | RIPK1 (0.35) | HTR2AHTR2CHTR2BHPGDRIPK1 | |
| SCHEMBL16501544 | 0.83 | SLC6A4 (0.47) | SLC6A4HTR6MCHR1PARP10HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003006-B2 | Difluorobenzene derivative and nematic liquid crystal composition using the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2011-08-23 | — | — | US | disclosed |
| US-20090200514-A1 | DIFLUOROBENZENE DERIVATIVE AND NEMATIC LIQUID CRYSTAL COMPOSITION USING THE SAME | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090200514-A1 | DIFLUOROBENZENE DERIVATIVE AND NEMATIC LIQUID CRYSTAL COMPOSITION USING THE SAME | TRPV2, HCN2, DVL1 | SLC6A4 3387/4885HTR6 4326/4885MCHR1 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.